Get the Stockscreener App
1,150.99
1.64%
-19.15
After Hours:
1152.12
1.13
+0.10%
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $1,150.99, with a volume of 2.15M.
It is down -1.64% in the last 24 hours and down -8.32% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$1,170.14
Open:
$1174.71
24h Volume:
2.15M
Relative Volume:
0.82
Market Cap:
$1.03T
Revenue:
$72.25B
Net Income/Loss:
$25.28B
P/E Ratio:
41.43
EPS:
27.781
Net Cash Flow:
$10.37B
1W Performance:
+1.16%
1M Performance:
-8.32%
6M Performance:
+26.41%
1Y Performance:
+54.09%
1-Day Range:
$1,145.98
$1,188.88
1-Week Range:
$1,134.41
$1,188.88
52-Week Range:
$712.05
$1,292.65
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,150.99 | 1.04T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
269.17 | 648.72B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
265.08 | 468.66B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
148.08 | 372.32B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
142.71 | 268.53B | 54.66B | 13.58B | 16.05B | 7.0171 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Downgrade | HSBC Securities | Hold → Reduce |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-16-25 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-15-25 | Reiterated | BofA Securities | Buy |
| Dec-15-25 | Reiterated | Goldman | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026 - GlobeNewswire Inc.
Eli Lilly stock ends the day 1.64 percent lower - AD HOC NEWS
Lilly CEO says state needs to emphasize quality of life, health care - Inside INdiana Business
Eli Lilly & Co. stock underperforms Wednesday when compared to competitors - MarketWatch
Lilly’s Ricks says state needs to emphasize quality of life, health care - ibj.com
Eli Lilly and Co. stock gains as Houston plant expands GLP-1 capacity - AD HOC NEWS
Why is Eli Lilly (NYSE:LLY) in focus amid today’s healthcare stocks discussion? - Kalkine Media
Eli Lilly CEO Says Foundayo Wins One-Third of New Oral GLP-1 Patients as Company Captures 70% of New Seniors: 'Growing Week on Week' - Yahoo Finance
Eli Lilly Could Be a ‘$2,000 Stock’ in the Next 3 to 4 Years, Says Home Depot Co-Founder Ken Langone - Benzinga
How should investors read the latest signal from Eli Lilly (NYSE:LLY)? - Kalkine Media
Eli Lilly and Co. stock heads into the open after a 0.61 percent gain - AD HOC NEWS
Florida Sues Lilly, Sanofi, CVS in Insulin Antitrust Action (3) - Bloomberg Government News
Should Eli Lilly (LLY) Investors Watch Its $6.5 Billion Houston GLP 1 Buildout? - Yahoo Finance
Eli Lilly stock ends the day 0.61 percent higher at USD 1,172.05 - AD HOC NEWS
GLP-1 makers Novo, Eli Lilly sued over sudden loss of vision in patients - NewsNation
Novo and Lilly Challenged: Viking Stock Surges on Weight-Loss Drug Trial - Barron's
Eli Lilly Gets Full FDA Approval for Inluriyo in ESR1-Mutated Breast Cancer - benzinga.com
Viking Therapeutics Stock Surges 36%+ Intraday. It Could Challenge Lilly and Novo's Obesity Empire - Moomoo
Ken Langone predicts Eli Lilly stock will hit $2,000 in 3-4 years, rivaling his Home Depot gains. - pluang.com
His Bet On Home Depot Made Ken Langone A Billionaire. Now He Sees Eli Lilly Stock Hitting $2,000 - 24/7 Wall St.
Eli Lilly CEO Delivers Urgent Message on the Company's Next Big Weight-Loss Pill - Yahoo Finance
Ken Langone on Eli Lilly: Could be a $2,000 stock in the next 3-4 years - CNBC
Eli Lilly Just Got a Big Boost From Medicare's GLP-1 Expansion - TradingView
Trump's Drug Price Achievements Questioned Following Separate Most Favored Nation Contract Disclosures wi - benzinga.com
Eli Lilly stock dips despite strong earnings; C... - pluang.com
Eli Lilly Breaks Ground on $6.5B GLP-1 Manufacturing Facility in Northeast Houston - REBusinessOnline
Eli Lilly CEO Says Foundayo Wins One-Third of New Oral GLP-1 Patients as Company Captures 70% of New Seni - benzinga.com
Eli Lilly breaks ground on $6.5B Houston manufacturing plant - Yahoo Finance
Eli Lilly and Co. stock gains as Foundayo demand expands - AD HOC NEWS
Eli Lilly & Co (LLY) Receives a Buy from Barclays - The Globe and Mail
Eli Lilly and Co. stock rises 1.04 percent ahead of the open - AD HOC NEWS
Medicare Spurs 700K Seniors to GLP-1s; Lilly Leads - Briefs Finance
Eli Lilly breaks ground on $6B Houston manufacturing facility - cbs19.tv
Eli Lilly and Company Breaks Ground on $6.5 Billion Houston Manufacturing Site - marketscreener.com
Eli Lilly stock ends the day slightly higher at the close - AD HOC NEWS
Eli Lilly (LLY) Increases Yet Falls Behind Market: What Investors Need to Know - Yahoo Finance
Eli Lilly and Company Breaks Ground in Houston, One of Ten U.S. Manufacturing Sites Announced Since 2020 - marketscreener.com
Eli Lilly Starts Building Record $6.5B Houston Manufacturing Facility - Bisnow
Eli Lilly breaks ground on $6.5B pharmaceutical factory in Houston - houston.innovationmap.com
Eli Lilly Stock (LLY) Rises After Company Provides Update on Obesity Pill Sales - TipRanks
What Lilly Stock's Breast Cancer Drug Approval Means For Shareholders - simplywall.st
Eli Lilly (LLY) Expands Market Share with Foundayo Amid Growing Demand - GuruFocus
Eli Lilly Stock Is On Track to Do Something It Hasn't Done Since 2016 - The Motley Fool
Eli Lilly breaks ground on $6.5B Houston plant, largest project of its kind in Texas history - The Business Journals
Eli Lilly CEO says 700,000 new seniors have started GLP-1s after Medicare coverage, and 70% are on Lilly drugs - CNBC
Eli Lilly CEO Says One-Third of New GLP-1 Pill Patients Starting on Foundayo - marketscreener.com
Eli Lilly to host groundbreaking of $6.5 billion facility at Houston’s Generation Park - CW39 Houston
Novo Nordisk Falls 7% as Post-Wegovy Growth Plan Fails to Ease Competition Fears; Eli Lilly Slips, Viking Therapeutics Edges Higher - 24/7 Wall St.
Novo says CagriSema shows greater weight loss than Lilly rival in diabetes patients - Reuters
Eli Lilly vs. Novo: The Obesity-Drug Battle Is Entering Its Next Round - Barchart.com
LLY - Finviz
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.01%
1.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):